Patent Expiry

Patent/Exclusivity Expiry: YUTREPIA

Other upcoming events for LQDA

Phase 3 ReadoutPhase 3 Topline: A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety and Tolerability of Liposomal Treprostini
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: YUTREPIA — LQDA Patent Expiry | BioSniper